GSK’s Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

GSK’s Ze­ju­la-Jem­per­li com­bo met its pri­ma­ry end­point in a tri­al in­ves­ti­gat­ing the drugs in first-line ad­vanced ovar­i­an can­cer, but missed on a key sec­ondary end­point …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.